New Orleans, LA— The oral investigational agent ozanimod, which is from the same drug class as fingolimod (Gilenya), may be as effective as fingolimod, with fewer safety concerns, for the treatment of patients with relapsing multiple sclerosis (MS), reported Brett E. Skolnick, PhD, Receptos, San Diego, CA, at the 2017 Consortium of Multiple Sclerosis Centers annual meeting. Dr Skolnick stepped in for the lead investigator Giancarlo Comi, MD, Vita-Salute San Raffaele University, Neurology, Milan, Italy, who was unable to attend the meeting.
Orlando, FL—A growing body of evidence supports vitamin D as a dietary factor associated with multiple sclerosis (MS). The question remains, however, whether low serum levels of vitamin D may predispose patients to MS, or whether low levels are a part of the disease, and whether supplementation is really protective. Regardless, the data are suggestive enough to make vitamin D supplementation part of MS management, according to Ellen Mowry, MD, Associate Professor of Neurology, Johns Hopkins University, Baltimore, MD, who discussed the topic at the 2017 Americas Committee for Treatment and Research in Multiple Sclerosis meeting.
FDA Approves First Tissue-Engineered Autologous Cellularized Scaffold Product for the Repair of Cartilage Defects
The FDA has approved Maci, the first tissue-engineered autologous cellularized scaffold product for the repair of symptomatic cartilage in adult patients with knee defects. Maci is composed of cells grown from the patient’s own healthy cartilage tissue, which are then placed onto a bioresorbable collagen membrane and surgically implanted over the area where the damaged tissue was removed.
Enhanced molecular understanding of primary brain tumors has driven recent advances in treatment, which have extended beyond chemotherapy and radiotherapy to include immunomodulatory agents and electromagnetic fields applied directly to the scalp. Andrew B. Lassman, MD, Chief, Division of Neuro-Oncology, Columbia University Medical Center, New York, NY, provided an overview of the latest developments in the treatment of brain tumors at the 2016 American Academy of Neurology annual meeting.
On April 29, 2016, the FDA approved oxycodone (Xtampza ER) extended-release (ER) capsules, an opioid agonist, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The US Food and Drug Administration (FDA) has approved etanercept-szzs, a biosimilar to etanercept (Enbrel), for the treatment of multiple inflammatory diseases, according to an announcement by the organization. The biosimilar injection has been approved to treat patients with moderate-to-severe rheumatoid arthritis; moderate-to-severe polyarticular juvenile idiopathic arthritis; active psoriatic arthritis; active ankylosing spondylitis; and chronic, moderate-to-severe plaque psoriasis.
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. Such mutations are present in approximately 10-20 percent of non-small cell lung cancers (NSCLC).
Page 1 of 6
Results 1 - 10 of 52
Results 1 - 10 of 52